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Abstract 
In the last decade trans-arterial radioembolization has 
given promising results in the treatment of patients 
with intermediate or advanced stage hepatocellular 
carcinoma (HCC), both in terms of disease control 
and tolerability profile. This technique consists of the 
selective intra-arterial administration of microspheres 
loaded with a radioactive compound (usually Yttrium90), 
and exerts its therapeutic effect through the radiation 
carried by these microspheres. A careful and meticulous 
selection of patients is crucial before performing 
the radioembolization to correctly perform the pro-
cedure and reduce the incidence of complications. 
Radioembolization is a technically complex and 
expensive technique, which has only recently entered 
clinical practice and is supported by scant results from 
phase Ⅲ clinical trials. Nevertheless, it may represent 
a valid alternative to transarterial chemoembolization 
(TACE) in the treatment of intermediate-stage HCC 
patients, as shown by a comparative retrospective 
assessment that reported a longer time to progression, 
but not of overall survival, and a more favorable safety 
profile for radioembolization. In addition, this treatment 
has reported a higher percentage of tumor shrinkage, 
if compared to TACE, for pre-transplant downsizing 
and it represents a promising therapeutic option in 
patients with large extent of disease and insufficient 
residual liver volume who are not immediately eligible 
for surgery. Radioembolization might also be a suitable 
companion to sorafenib in advanced HCC or it can 
be used as a potential alternative to this treatment 
in patients who are not responding or do not tolerate 
sorafenib.
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Core tip: This review provides an overview of trans-
arterial radioembolization, a new therapeutic option for 
patients with hepatocellular carcinoma. In particular, 
the practical aspects of the technique and available data 
on disease control will be presented, with reference to 
patients in either early or advanced stages of disease, 
treated with trans-arterial embolization alone or within 
combination regimens.
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INTRODUCTION
Hepatocellular carcinoma (HCC) ranks fifth among 
the most common cancers worldwide and represents 
the third most frequent cause of cancer-related 
mortality[1,2]. In the majority of cases, HCC is dia-
gnosed in the intermediate-advanced stage [stage B 
and C according to the Barcelona Clinic Liver Cancer 
(BCLC) staging categories], when radical therapy is no 
longer possible. A number of curative and/or palliative 
therapies are available in this setting, but they are not 
always characterized by a favorable safety/efficacy ratio. 
Therefore, new therapeutic options are eagerly awaited.
Preliminary data on the use of trans-arterial radio-
embolization have demonstrated a good tolerability 
profile and promising results of this technique in terms 
of disease control. Although radioembolization has been 
studied more extensively in BCLC-B and BCLC-C HCC 
patients, its use has been evaluated also in the early 
stages (BCLC-A). 
This review provides an overview of trans-arterial 
radioembolization. In particular, the practical aspects 
of the technique and available data on disease control 
will be presented, with reference to patients in either 
early or advanced stages of disease, treated with 
trans-arterial embolization alone or within combination 
regimens.
TRANS-ARTERIAL RADIOEMBOLIZATION: 
GENERAL CONCEPTS
Trans-arterial radioembolization, also known 
simply as radioembolization or as selective internal 
radiation therapy, consists of the selective intra-
arterial administration of microspheres loaded with a 
radioactive compound - usually Yttrium90 or Lipiodol 
labelled with iodine131 or rhenium188 - through a 
percutaneous access.
Yttrium90 is a pure β emitter characterized by 
short half-life (64.2 h) and limited tissue penetration 
(average 2.5 mm, maximum 11 mm). Two types of 
microspheres are available, namely TheraSphere®, 
made of glass, and Sir-Spheres®, made of resin. They 
differ in size, activity for individual bead, and number 
of microspheres injected (as shown in Table 1), but 
available data suggest the equivalence of the two 
methods[3]. Differing from other embolizing treatments 
such as trans-arterial chemoembolization (TACE), 
radioembolization does not exert a macroembolic 
effect: therefore, both the benefits and the toxic 
effects of the treatment are dependent upon the 
radiation carried by the microspheres and not by any 
ischemic effect.
The different features of the two types of micro-
spheres can explain the hypothetical different use 
for each patient and the difference in the mode of 
administration and in the activity calculation. 
TheraSphere has a minimal embolic power (average 
number of glass microspheres injected: 4 million) with 
a higher activity for each sphere (2500 Bq vs 50 Bq for 
Sir-Spheres). These characteristics prevent vascular 
stasis and reflux during the administration, but in the 
case of a large lesion an inadequate coverage of the 
treated volume can occur, because the higher specific 
weight can limit the distribution of the microspheres.
On the other hand, Sir-Spheres, with a higher 
number of microspheres injected (average 40 million), 
have an important embolic power. Thanks to the 
number of microspheres injected it is possible to 
achieve an adequate and more homogeneous coverage 
of the lesion when compared with TheraSphere; 
however, the higher embolic power requires slow 
injections and accurate angiographic control during the 
administration.
The different coverage of the lesion is also reflected 
by the different median lethal dose: for Therasphere 
it oscillates between 205[4] and 257 Gy[5], instead for 
Sir-Spheres we can find a lower value, 120 Gy[6]. Of 
note, these values were calculated with the dosimetric 
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Table 1  Main characteristics and differences between TheraSphere® 
and Sir-Spheres
Sir-Spheres® TheraSphere®
Diameters (μm) 32 ± 10 22 ± 10 
Specific weight (g/dL) 1.6 3.6
Activity per microsphere to date 
calibration (Bq)
50 2500
Number of microsphere (vial, million) 40-80 1.2-8 
Material Resin Glass
Activity in the vial (GBq) 3% ± 10% 3, 5, 7, 10, 15 or 20
approach, which differs from the empiric activity 
calculation method (described below).
The first studies on Yttrium90 for the treatment 
of oncological diseases date back to the 1960s[7,8]. 
However, radioembolization has entered clinical practice 
only in the last decade. Available evidence supports the 
potential effectiveness of Yttrium90 microspheres in the 
treatment of primary (HCC and cholangiocarcinoma) 
and metastatic liver cancer[9-12].
Methods
Radioembolization can be divided into consecutive 
stages: (1) patient pre-selection: a multidisciplinary 
assessment identifies patients possibly eligible for 
this therapy[13]; (2) patient selection: a diagnostic 
angiography is performed with the aim of evaluating 
vascular anatomy and to identify and embolize 
any extrahepatic branch which could disperse the 
microspheres to non-target organs[14]. Moreover, 
angiography allows the establishment of the most 
appropriate point of injection of the catheter. During 
this visit, macroaggregates of albumin (MAA) labeled 
with Tc99 are injected. They present a diffusion similar 
to that of radioembolization microspheres, and can 
help predict the distribution of the microspheres. The 
diffusion of these macroaggregates is studied by a 
single photon emission computed tomography (SPECT/
CT), performed within 1 h from the injection[15]; After 
the selection phase, other contraindications might 
exclude patients from treatment. Among these, 
a hepato-pulmonary shunt > 20% of the injected 
dose[16] or vascular abnormalities not correctable by 
embolization; (3) dose calculation: the amount of 
Yttrium90 administered is determined specifically for 
each patient (as discussed below); and (4) injection of 
microspheres: microspheres are injected by a catheter 
no later than 4 wk from the selection of patients. 
Dose calculation
All the calculation activity methods used today are 
generally based on empiric data.
In order to perform the calculation of the activity (A) 
of TheraSphere to be injected, the following formula is 
generally used:
A = 120 (Gy) × M/[(1 - S) × 50]. Where M is 
the mass of the whole liver and S is the lung-liver 
shunt. 120 Gy is the dose (lethal dose) that we want 
to disburse to the lesion, assuming that there is a 
uniform distribution of the glass spheres in the target 
volume[17].
For Sir-Sphere, 3 methods are available for 
calculation activity[18]: (1) Empirical Method[18]. The 
amount of activity to be injected is chosen in relation 
to tumor over whole liver percentage (T): T < 25% → 
Gbq; 25% < T ≤ 50% → 2.5 GBq; T > 50% → 3 Gbq. 
With this method however, the dose to healthy liver is 
not considered and patients could be exposed to non-
necessary radiation toxicity; (2) BSA-Method[18]. In the 
calculation of activity to be injected, the ratio between 
tumor lobe (where the lesion is localized) and whole 
liver volumes and the body surface area (BSA) of 
the patient are considered. This method accounts for 
the relation between the size of the patient and their 
liver and enables the treatment of different lesions 
in separate lobes, preserving healthy tissues; and 
(3) Partition model[16]. Following the Medical Internal 
Radiation Dose (MIRD) method, the partition model 
takes into account the different distribution of the 
microspheres in the lesions and in the healthy tissue. 
The evaluation of these distributions is based on the 
results of the SPECT/TC with 99mTc-MAA. A (GBq) = 
Dliver × [(T/N × Mtumor) + Mliver]49670 × (1 - S). 
Where Dliver is the dose to healthy liver (chosen by 
nuclear medicine physician in order to preserve it), 
Mliver is the whole organ mass, Mtumor is lesion mass, 
S is the lung-liver shunt and T/N is the ratio between 
activity over mass for tumor and liver: T/N = (Alesion/
Mlesion) (Aliver/Mliver). This method is indicated in 
patients who have compromised hepatic functionality.
Another possible approach is voxel dosimetry, in 
which the calculation of the activity takes into account 
the biological damage required for tumor and healthy 
cells[5]. The final aim of this method, which is based on 
the evaluation of the real distribution, voxel by voxel, 
of the microspheres, simulated by 99mTc-MAA, is to 
treat the lesions with high doses, without overcoming 
the dose constraint to healthy liver, chosen for the 
single patient. Following this approach, it is possible 
to maximize the treatment of the lesion while limiting 
liver toxicity and thus giving the chance of a more 
specific and individualized cure to each patient[5].
The simulation by 99mTC-MAA is important not 
only to determine the dose delivered to the injected 
healthy liver, but also as a predictive factor. Garin et 
al[4] reported that quantitative 99mTC-MAA SPECT/CT 
is predictive of response to treatment, progression 
free survival (PFS) and overall survivial (OS), and 
has therefore a fundamental role in the selection of 
patients and the adaptation of treatment planning. 
The personalization of the activity planning could be 
further improved by using dual-tracer 99m Tc-MAA- 
99m Tc-SC fusion SPECT, an imaging tool that merges 
data on radioactivity distribution with physiologic liver 
mapping that has been recently presented by Lam and 
colleagues[19].
Management of complications
Complications of radioembolization are either caused 
by delivering a toxic dose to non-tumoral tissues, 
or by procedural complications during the catheter’s 
placement and manipulation. The main complications 
include: (1) liver failure or radio-induced liver disease 
(RILD)[20,21], with an incidence up to 4%; (2) biliary 
complications[22] (incidence < 10%); (3) post-
radioembolization syndrome (PRS), characterized by 
fatigue, nausea, vomiting, anorexia, fever, abdominal 
pain[23,24] (incidence 20%-55%); (4) gastrointestinal 
complications, with an incidence < 5% when an 
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Radioembolization for intermediate-stage HCC
Patients with intermediate-stage (BCLC-B) HCC 
represent a very heterogeneous population[34,35]. TACE 
is usually considered the treatment of choice in this 
setting, although alternative loco-regional and medical 
(sorafenib) treatment do retain efficacy. In addition, 
the use of TACE is limited by a number of absolute 
and relative contraindications[36]. In this population of 
patients, radioembolization may be a viable therapeutic 
option, given the low incidence of associated adverse 
effects. 
To date, no randomized trials have directly 
compared radioembolization and TACE in patients with 
intermediate-stage HCC, available data are therefore 
based mainly on retrospective assessments.
Salem et al[37] compared 123 patients treated with 
radioembolization with 122 subjects who had received 
TACE: overall, median time to progression - but not 
overall survival - was longer after radioembolization 
(13.3 mo vs 8.4 mo, P = 0.046), and this latter 
intervention was also associated with a more favorable 
safety profile. Similar results have been reported by 
other authors[38-41]. For instance, a very recent study 
by El Fouly et al[41] has shown that radioembolization 
presents a similar efficacy, but a lower incidence of 
adverse events and need for hospitalization when 
compared with TACE. From a healthcare-utilization 
perspective, radioembolization is definitely more 
complex and expensive than TACE; however, TACE 
requires more frequent, repeated treatments than 
radioembolization and may be associated with a less 
favorable safety profile, thus increasing indirect costs. 
A retrospective analysis has also suggested that 
both radioembolization and sorafenib are effective 
in patients with intermediate-stage HCC, and are 
associated with a similar survival[42].
Radioembolization for downsizing
In the large population of intermediate-stage HCC 
patients, tumor shrinkage, or “downsizing” may 
convert the disease to surgical resectability or may 
offer the opportunity for transplant[43]. Several options, 
either percutaneous or trans-arterial, are now available 
to achieve tumor downsizing, and radioembolization 
has become part of this armamentarium.
A retrospective study has compared radio-
embolization and TACE for pre-transplant downsizing, 
and has shown that the percentage of tumor shrinkage 
was higher after radioembolization (58% vs 31%, P = 
0.023)[44].
Radioembolization also represents a promising 
therapeutic option in patients with large extent of 
disease and insufficient residual liver volume, who 
are therefore not immediately eligible for surgery. 
In these patients, portal vein embolization (PVE) 
has been proposed to induce hypertrophy of the 
contralateral lobe and make surgical resection possible. 
accurate angiographic phase is performed[25,26]; and 
(5) radio-induced pneumonia, whose incidence is 
< 1% if the hepato-pulmonary shunt is adequately 
calculated[27,28].
A careful and meticulous selection phase is 
crucial to reduce the incidence of complications. In 
addition, there is some consensus on the use of pre-
medications to help prevent complications, such as 
proton pump inhibitors (starting one week before 
treatment and continuing for one month after the 
procedure), corticosteroids (for approximately 5 d from 
the interventions to reduce the incidence of PRS)[29], 
antiemetics and analgesics before the interventions 
and as needed.
RADIOEMBOLIZATION IN HCC 
TREATMENT: CURRENT EVIDENCE
Since radioembolization has only recently entered 
clinical practice, results from phase Ⅲ clinical trials 
are still scant. As a consequence, radioembolization is 
not currently listed among possible treatment options 
for HCC in some guidelines such as those issued by 
the American Society of Clinical Oncology. However, 
other scientific societies such as the European Society 
of Medical Oncology consider radioembolization as a 
promising therapeutic option either as a “bridging” 
treatment or as the main therapy for patients with 
diffuse intrahepatic tumor spread[30]. In addition, the 
National Comprehensive Cancer Network guidelines 
consider radioembolization suitable for patients with 
unresectable disease due to inadequate hepatic 
reserve, poor performance status, comorbidities, 
or specific location and extension of the tumor[31]. 
Lastly, according to the National Cancer Institute 
(NCI) recommendations, radioembolization may be 
considered in selected patients with liver-confined 
HCC, who are not eligible for transplant or resection[32].
Thanks to its versatility, radioembolization has been 
evaluated in different clinical situations, as summarized 
in the following paragraphs.
Radioembolization for early stage HCC
Patients with early-stage (BCLC-A) HCC are candidates 
for curative treatments such as liver transplant. 
However, the low number of donors and the long 
waiting list expose patients to the risk of disease 
progression, with subsequent withdrawal from the 
waiting list.
Therefore, patients on the waiting list are fre-
quently treated with locoregional approaches, such as 
percutaneous ablation or TACE, in order to limit the 
risk of local progression. 
Recently, radioembolization has been proposed 
as a valuable therapeutic option for patients on the 
transplant waiting list[33], although this approach is not 
widely performed due to its procedural costs.
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However, PVE is associated with some risks of tumor 
progression within the liver lobe during hypertrophy. 
Radioembolization can induce a marked hypotrophy 
of the treated hepatic lobe, associated with an evident 
hypertrophy of the contralateral lobe (the so-called 
“radiation lobectomy”)[45]. Therefore, radioembolization 
has been proposed as an alternative to PVE in HCC 
patients. In addition, radioembolization offers the 
advantage of treating the cancer itself, thus reducing 
the risk of pre-interventional tumor progression, and 
represents a therapeutic option also in patients with 
neoplastic venous thrombosis[46]. Of note, 6-12 wk 
are necessary to achieve radiation lobectomy; during 
this time span, patients with more favorable biological 
tumor behavior and who may therefore gain most 
benefit from surgical resection can be identified[46].
Radioembolization for advanced stage HCC
Sorafenib represents the treatment of choice in patients 
with advanced stage (BCLC-C) HCC, and is associated 
with an overall survival of about 11 mo[47-50]. The overall 
survival associated with radioembolization in this setting 
ranges from 6 to 10 mo[9,10]; given its good safety 
profile, radioembolization might represent a potential 
alternative to sorafenib in selected patients who are not 
responding or do not tolerate this treatment. Of note, 
the preliminary results of the SORAMIC randomized 
trial, which compares radioembolization plus sorafenib 
with sorafenib alone in BCLC-C HCC patients, have 
shown that radioembolization followed by sorafenib 
appears to be as well tolerated as sorafenib alone[51]. 
Among patients with advanced HCC, radioem-
bolization may provide the best outcome in subjects 
with PVT involving segmental or lobar branches, where 
the median overall survival has reached 17 mo with 
glass microspheres[37,52] and 23.2 mo using MAA SPECT/
CT based dosimetry[53]. This compares with a median 
survival of 3-6 mo for patients with PVT of the common 
portal trunk. Less satisfactory results are documented 
for patients with distant metastases[12,54].
DIFFERENT CRITERIA TO EVALUATE THE 
OUTCOMES OF RADIOEMBOLIZATION
The therapeutic effects of radioembolization are 
evaluated mainly by the changes in the level of tumor 
markers and by radiological findings[55,56].
Tumor markers, in particular α-fetoprotein, are 
usually non-specific[57]. A decrease of α-fetoprotein 
may suggest a good response to treatment, but its 
increase does not provide any well-grounded clinical 
indication, as it can be determined not only by tumor 
progression, but also by lithic phenomena, infectious 
diseases or changes in liver function.
Imaging therefore becomes paramount to eva-
luate the response to treatment and therefore guide 
therapeutic choices. To this end, the American Association 
for the Study of Liver Diseases has proposed the 
“mRECIST criteria”[58]: according to mRECIST, the 
response to a given treatment is evaluated according to 
the reduction of the diameter of vital residual portion. 
These criteria have been shown to be accurate in 
identifying the complete necrosis of tumor mass after 
radioembolization[59]. However, post-radioembolization 
diagnostics still remain an open issue, especially in 
patients with partial response or stable disease - 
which represent the majority of cases. In fact, tumor 
necrosis is often irregular in distribution and contrast 
enhancement, making it difficult to measure vital 
portions. Therefore, the routine use of volumetric 
measurements of tumor necrosis have been proposed 
as a more accurate, reproducible and sensitive method 
for the early identification of responding patients[60,61].
The optimal time for the evaluation of treatment 
response is also debated. Although the first dimensional 
changes may already be observed after 1 mo, it is 
widely accepted that at least 3 to 4 mo are necessary 
to reliably estimate the actual response and therefore 
evaluate whether re-treatment may be considered.
CONCLUSION
Radioembolization represents a feasible and promising 
therapy for the treatment of all stages of HCC. 
Although it is technically complex and expensive, 
radioembolization may represent a valid alternative to 
TACE in intermediate-stage HCC and may be a suitable 
companion to sorafenib in advanced HCC.
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